LEO Pharma UK/Ireland markets prescription-only medicines to treat severe skin diseases, such as psoriasis and infected eczema, and thrombosis. The company has a record of joint working with the NHS.
Dr Kolli has extensive pharmaceutical industry and NHS experience, most recently as Acting Global Medical Affairs Director at GSK’s Neuroscience Centre of Excellence.
He has also held senior medical affairs and compliance roles at companies including AstraZeneca and Schwartz Pharma.
Geraldine Murphy, Managing Director of LEO Pharma UK/Ireland, said: “I am delighted to welcome Sathish to head up our medical team in the UK and Ireland.
“I am confident that his leadership, together with extensive clinical knowledge and pharmaceutical expertise gained across several different therapy areas, will prove to be invaluable to our dermatology and thrombosis teams and help us in our quest to deliver improved outcomes to patients.”
Dr Kolli praised LEO’s “patient-centred” approach, saying: “LEO are not just talking about putting the patient first, they are actually living this value with their ‘total care solutions’, patient support programmes and joint working projects in the UK.
“Their Foundation status allows them to implement these over the long term and demonstrate their value.”
LEO Pharma UK is based in Princes Risborough, Buckinghamshire; LEO Ireland is based in Dublin.
Based in Denmark, LEO Pharma markets dermatology products in more than 100 worldwide. It is owned by the LEO Foundation.